Antigen-specific therapy for autoimmune diseases
A chimeric molecule targeting specific autoimmune disease markers through autoantigens and linkers offers personalized and effective treatment for autoimmune diseases, overcoming limitations of current therapies.
WO2026096624A1PCT designated stage Publication Date: 2026-05-07BODHI BIO LLC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- BODHI BIO LLC
- Filing Date
- 2025-10-29
- Publication Date
- 2026-05-07
Smart Images
Figure IMGF000026_0001 
Figure IMGF000026_0002 
Figure IMGF000027_0001
Abstract
A platform for therapy provides: a chimeric molecule comprising one or more auto-antigens linked by a linker to a fluorescent protein; a chimeric molecule comprising three or more components linked by linker, the components comprising two or more auto-antigens of an autoimmune disease and one or more ablative molecule and / or toxin or one or more fluorescent molecules; a chimeric molecule comprising two or more components linked by linker, the components comprising an antibody or an antigen binding fragment thereof to an autoimmune disease associated HLA class or HLA class II molecule and one or more ablative molecules and / or toxins or one or more fluorescent molecules; and a chimeric molecule comprising two or more components linked by linker, the components comprising an antibody or an antigen binding fragment thereof to a disease associated T-cell receptor and one or more fluorescent molecules or one or more ablative molecule and / or toxin
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Antigen surrogates in autoimmune disease
US20140147455A1
Diagnosis, prevention, and / or treatment of autoimmune diseases
WO2018031947A1
Compositions and methods for antigen-specific therapy
WO2023183477A1